68 citations
,
April 2012 in “Digestive and Liver Disease” This study found that both Elental and 6-mercaptopurine were effective for maintaining remission in Crohn's disease, without a significant difference between them over 24 months.
April 2023 in “Journal of Investigative Dermatology” This study found that long-term imiquimod treatment on mice intensified skin inflammation early on, but topical corticosteroids significantly reduced skin infiltration and inflammatory cytokines after initial inflammation subsided.
16 citations
,
April 2006 in “Pediatrics International” This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.
January 2018 in “Practical diabetes” In this study, leflunomide was effective in treating rheumatoid arthritis, showing comparable efficacy to methotrexate and greater response rates than sulfasalazine, but has significant side effects that require monitoring.
November 2020 in “Universal Journal of Pharmaceutical Research” In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
January 2018 in “Journal of Crohn s and Colitis” This study found that high-dose intravenous ferric carboxymaltose may reduce inflammatory activity in patients with inflammatory bowel disease and iron deficiency anaemia, as evidenced by decreased CRP levels and improved clinical disease indices.
October 2018 in “The American journal of gastroenterology” This case study highlights the importance of early detection and management of pembrolizumab-induced hepatitis, suggesting that early steroid treatment could potentially prevent severe complications.
19 citations
,
September 2006 in “Journal of Pediatric Gastroenterology and Nutrition” In this case study, a 12-year-old girl with severe Crohn colitis achieved impressive clinical and endoscopic remission after receiving infliximab and azathioprine as first-line treatment, suggesting potential benefits of early intensive therapy.
39 citations
,
September 2015 in “Clinical Therapeutics” This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.
9 citations
,
June 2013 in “Australasian Journal of Dermatology” This case study reports on an adult with metastatic Crohn's disease treated with infliximab over 4.5 years, providing valuable follow-up data in this context.
45 citations
,
March 1998 in “Journal of the American Academy of Dermatology” This report describes two cases of Majocchi's granuloma in immunocompromised patients, highlighting the importance of considering this condition in such populations.
3 citations
,
June 1983 in “Archives of Dermatology” This article discusses the effectiveness of adrenal cortex compounds E and F in treating connective tissue disorders like rheumatoid arthritis and lupus erythematosus, but it reports no new clinical results.
1 citations
,
October 2013 in “The American Journal of Gastroenterology” This case report documents a 59-year-old woman who developed atypical drug-induced lupus after receiving infliximab for Crohn's disease, with symptoms persisting even after discontinuation.
1 citations
,
October 2015 in “The American journal of gastroenterology” This study reported two cases where infliximab-associated psoriasiform alopecia resolved with significant hair regrowth after stopping infliximab and using potent topical steroid treatment.
March 2005 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
35 citations
,
August 2001 in “Journal of Cutaneous Medicine and Surgery” This paper reviews the use of tacrolimus for various conditions, noting its effectiveness in treating certain skin disorders but highlighting that some findings remain anecdotal due to limited case numbers.
25 citations
,
October 2010 in “Journal of Hepatology” This study presented a case where budesonide was insufficient to maintain remission in autoimmune hepatitis, suggesting it may be less effective than prednisolone and associated with notable steroid side effects.
January 2024 in “Journal of Crohn's and colitis” This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.
December 2017 in “The Sri Lanka Journal of Dermatology” This study reports a case where treatment with the TNF alpha inhibitor infliximab successfully resolved refractory alopecia universalis in a 41-year-old woman.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
September 2010 in “Middle East Journal of Digestive Diseases” This case report highlights that treating ulcerative colitis with azathioprine and mesalamine led to hair regrowth in a middle-aged man with recent onset alopecia universalis, suggesting skin manifestations can be an extraintestinal indication of the disease.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” This study observed that 6.45% of IBD patients treated with anti-TNF therapy developed severe psoriasiform reactions, with notable cases of alopecia universalis suggesting a potential link to previous alopecia areata.
51 citations
,
July 2003 in “Annals of the Rheumatic Diseases” This case study reports a successful use of co-trimoxazole in treating a 13-year-old girl with symptoms suggestive of autoimmune disorders and relapsing polychondritis.
December 2024 in “PubMed” This study reports a case where cyclosporine effectively treated a 51-year-old woman with idiopathic follicular mucinosis resistant to other therapies, suggesting its potential as an option for refractory cases.
1 citations
,
October 2024 in “The American Journal of Gastroenterology” In this case report, a patient with Crohn's disease experienced alopecia and psoriasiform reactions attributed to anti-TNF therapy, which improved after switching to Ustekinumab.
53 citations
,
August 2014 in “Cochrane library” This review found no evidence supporting the efficacy of methotrexate for inducing remission in active ulcerative colitis compared to placebo or active comparators.
February 2018 in “The American Journal of Gastroenterology” This study observed that intravenous ferric carboxymaltose did not inhibit the drug-induced reduction of inflammatory activity in patients with inflammatory bowel disease, as indicated by lower CRP levels.
8 citations
,
September 2006 in “Transplantation” In this reported case, an immunosuppressive regimen including tacrolimus and mycophenolate mofetil was associated with a total regression of hidradenitis suppurativa activity over one year, while cyclosporine alone had no effect.
11 citations
,
March 2010 in “PubMed” This study concluded that monthly pulse IV cyclophosphamide therapy was effective in achieving complete or partial remission in 68.9% of Indian patients with severe lupus nephritis, though longer follow-up is needed.